Compare LDI & ACHV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LDI | ACHV |
|---|---|---|
| Founded | 2010 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 607.4M | 618.0M |
| IPO Year | 2021 | 2018 |
| Metric | LDI | ACHV |
|---|---|---|
| Price | $1.01 | $6.10 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | $3.00 | ★ $14.67 |
| AVG Volume (30 Days) | 1.9M | ★ 2.2M |
| Earning Date | 05-05-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $17.58 | N/A |
| Revenue Next Year | $13.99 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.95 | $2.38 |
| 52 Week High | $5.05 | $7.11 |
| Indicator | LDI | ACHV |
|---|---|---|
| Relative Strength Index (RSI) | 36.43 | 51.78 |
| Support Level | N/A | $4.09 |
| Resistance Level | $1.32 | $7.11 |
| Average True Range (ATR) | 0.07 | 0.40 |
| MACD | -0.01 | -0.05 |
| Stochastic Oscillator | 29.45 | 38.86 |
loanDepot Inc provides nonbank consumer lending solutions for individuals in the United States. It offers personal, residential home, home refinancing, mortgage and home equity loans. It serves customers through distribution channels, including consumer direct centres, retail branches, wholesale centres, and consumer finance and servicing centres in the United States. It competes with commercial banks and financial institutions.
Achieve Life Sciences Inc is a late-stage clinical specialty pharmaceutical company with the sole mission to address the nicotine dependence epidemic through the development and commercialization of cytisinicline. Cytisinicline, is a naturally occurring alkaloid. Additionally, The company has completed a Phase 2 study with cytisinicline in vaping cessation and conducted a successful end-of-Phase 2 meeting with the FDA for a future vaping indication. It operates in one operating segment, development and commercialization of cytisinicline for nicotine dependence, with operations located in Canada, the United States and the U.K.